Luis Navazo, MD
Family Medicine · Oceanside, CANPI 1043359219
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $98,679 of the $162,244 with a category attached, or 60.8%. 60 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 48.2% of the total. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 581 payments — averaging $279.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$78K
- Teva Pharmaceuticals USA, Inc.$61K
- Kerecis Limited$12K
- Boston Scientific$1K
- Novartis$1K
- Lilly USA, LLC$833
- plus $8K from 54 others
Across 1 payment — averaging $10,675 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kerecis Limited$11K
What the payments were for
- Consulting fees$28,08617%
- Speaking & faculty fees$98,67961%
- Travel & lodging$18,38511%
- Food & beverage$16,59010%
- Education$4920%
- Gifts$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$70,766
- AUSTEDO$31,420
- Kerecis Omega3 Marigen$30,008
- Austedo XR$27,809
- Kerecis Omega3 SurgiClose$16,148
- Kerecis SurgiClose$6,556
- Kerecis Omega3 GraftGuide$3,144
- Kerecis GraftGuide$1,639
- WATCHMAN Access System$631
- Watchman$569
- QBW251$565
- ARISTADA$459
- Apligraf$324
- Restrata Wound Matrix$260
- FARXIGA$234
- REXULTI$232
- BREZTRI$129
- AIRSUPRA$125
- VERQUVO$125
- Dayvigo$122
How this compares
$162,244 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 33 | $233,608 |
| EliquisApixaban | 407 | $209,442 |
| XareltoRivaroxaban | 384 | $182,971 |
| MounjaroTirzepatide | 132 | $137,991 |
| FarxigaDapagliflozin Propanediol | 209 | $110,453 |
| AustedoDeutetrabenazine | 17 | $98,673 |
| XifaxanRifaximin | 38 | $71,657 |
| VascepaIcosapent Ethyl | 238 | $65,089 |
| DapagliflozinDapagliflozin Propanediol | 101 | $40,614 |
| MyrbetriqMirabegron | 69 | $33,589 |
| EntrestoSacubitril/Valsartan | 64 | $33,474 |
| TrulicityDulaglutide | 26 | $32,761 |
| RexultiBrexpiprazole | 24 | $31,731 |
| OzempicSemaglutide | 33 | $31,388 |
| JanuviaSitagliptin Phosphate | 42 | $24,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $78,257 | $233,60833 claims |
| PfizerEliquis | $142 | $209,442407 claims |
| Johnson & JohnsonXarelto | $348 | $182,971384 claims |
| Lilly USA, LLCMounjaro, Trulicity | $833 | $170,752158 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $709 | $120,900226 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $61,020 | $98,67317 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $43 | $71,65738 claims |
| Novo NordiskOzempic, Rybelsus | $224 | $42,66046 claims |
| Astellas Pharma US IncMyrbetriq | $234 | $33,58969 claims |
| NovartisEntresto | $1,312 | $33,47464 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $450 | $31,73124 claims |
| MerckJanuvia | $252 | $24,07742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Oceanside
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.